Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI

Neurology

Volumn 80, Issue 12, 2013, Pages 1124-1132

  Vos, Stephanie J B ^a   Van Rossum, Ineke A ^b   Verhey, Frans ^a   Knol, Dirk L ^b   Soininen, Hilkka ^c   Wahlund, Lars Olof ^d   Hampel, Harald ^e   Tsolaki, Magda ^f   Minthon, Lennart ^g   Frisoni, Giovanni B ^h   Froelich, Lutz ⁱ   Nobili, Flavio ^j   Van Der Flier, Wiesje ^b   Blennow, Kaj ^k   Wolz, Robin ^l   Scheltens, Philip ^b   Visser, Pieter Jelle ^a,b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e GOETHE UNIVERSITY   (Germany)

^f ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^g LUND UNIVERSITY   (Sweden)

^h IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

ⁱ UNIVERSITY OF HEIDELBERG   (Germany)

^j UNIVERSITY OF GENOA   (Italy)

^k SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^l IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN SIZE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; DISEASE SEVERITY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NONAMNESTIC MILD COGNITIVE IMPAIRMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; SENSITIVITY AND SPECIFICITY;

AGED; ALZHEIMER DISEASE; AMNESIA; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; COHORT STUDIES; EARLY DIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; TAU PROTEINS;

EID: 84876256314     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318288690c     Document Type: Article

References (30)

1. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging and Alzheimer's Association Workgroup. Alzheimers Dement 2011;7:270-279.
2. Landau SM, Harvey D, Madison CM, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010;75:230-238.
3. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009;65:403-413.
4. Devanand DP, Pradhaban G, Liu X, et al. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology 2007;68:828-836.
5. Fleisher AS, Sowell BB, Taylor C, et al. Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology 2007;68:1588-1595.
6. Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 2009;66:200-208.
7. Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 2009;8:619-627.
8. Hampel H, Wilcock G, Andrieu S, et al. Biomarkers for Alzheimer's disease therapeutic trials. Prog Neurobiol 2011;95:579-593.
9. Vos S, van Rossum I, Burns L, et al. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiol Aging 2012;33:2272-2281.
10. van Rossum IA, Vos SJB, Burns L, et al. Injury markers predict time to dementia in subjects with MCI and amyloid pathology. Neurology 2012;79:1809-1816.
11. Visser PJ, Verhey FRJ, Boada M, et al. Development of screening guidelines and clinical criteria for predementia Alzheimer's disease. Neuroepidemiology 2008;30:254-265.
12. Bouwman FH, Schoonenboom SNM, van der Flier WM, et al. CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging 2007;28:1070-1074.
13. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183-194.
14. Scheltens P, Barkhof F, Leys D, et al. A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci 1993;114:7-12.
15. Fazekas F, Kleinert R, Offenbacher H, et al. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology 1993;43:1683-1689.
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Washington, DC: American Psychiatric Association; 1994.
17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
18. Andreasen N, Hesse C, Davidsson P, et al. Cerebrospinal fluid {beta}-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 1999;56:673-680.
19. Blennow K, Wallin A, Ågren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical diagnostic marker for axonal degeneration in Alzheimer's disease? Mol Chem Neuropathol 1995;26:231-245.
20. Kolen M, Brennan R. Test Equating: Methods and Practices. New York: Springer-Verlag; 1995.
21. Sjogren M, Vanderstichele H, Ågren H, et al. Tau and Aβ42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem 2001;47:1776-1781.
22. Hulstaert F, Blennow K, Ivanoiu A, et al. Improved discrimination of AD patients using [beta]-amyloid(1-42) and tau levels in CSF. Neurology 1999;52:1555-1562.
23. Wolz R, Aljabar P, Hajnal JV, Hammers A, Rueckert D. LEAP: learning embeddings for atlas propagation. Neuroimage 2010;49:1316-1325.
24. Heagerty PJ, Lumley TL, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000;56:337-344.
25. R Development Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing. 2009.
26. Jack CR, Wiste HJ, Vemuri P, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 2010;133:3336-3348.
27. van Rossum IA, Vos S, Handels R, Visser PJ. Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. J Alzheimers Dis 2010;20:881-891.
28. Elias-Sonnenschein LS, Viechtbauer W, Ramakers IH, Verhey FR, Visser PJ. Predictive value of APOE-e4 allele for progression from MCI to AD-type dementia: a meta-analysis. J Neurol Neurosurg Psychiatry 2011;82:1149-1156.
29. Leoni V. The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease. Clin Chem Lab Med 2011;49:375-383.
30. Jungwirth S, Zehetmayer S, Hinterberger M, Tragl KH, Fischer P. The validity of amnestic MCI and non-amnestic MCI at age 75 in the prediction of Alzheimer's dementia and vascular dementia. Int Psychogeriatr 2012;24:959-966.